Compare
Staar Surgical Co vs RxSight, Inc. vs Warby Parker Inc. vs Cooper Companies, Inc.
| Latest fiscal year | Staar Surgical Co STAA | RxSight, Inc. RXST | Warby Parker Inc. WRBY | Cooper Companies, Inc. COO |
|---|---|---|---|---|
| Year ended | 2026-01-02 | 2025-12-31 | 2025-12-31 | 2025-10-31 |
| Revenue | $239.44M | $134.48M | $871.90M | $4.09B |
| Revenue growth (YoY) | -23.7% | -3.9% | +13.0% | +5.1% |
| Gross margin | 76.2% | 76.6% | 54.0% | 65.5% |
| Operating margin | -38.3% | -35.8% | -0.6% | 16.7% |
| Net margin | -33.6% | -29.0% | 0.2% | 9.2% |
| Net income | -$80.45M | -$38.94M | $1.64M | $374.90M |
| EPS (Diluted) | -$1.62 | -$0.95 | $0.01 | $1.87 |
| Operating cash flow | -$34.23M | -$15.51M | $110.78M | $796.10M |
| Free cash flow | -$40.05M | -$19.34M | $43.74M | $433.70M |
| Cash & equivalents | $153.15M | $19.95M | $286.36M | $110.60M |
| Total assets | $451.68M | $311.81M | $720.92M | $12.39B |
| Total liabilities | $107.49M | $36.13M | $353.19M | $4.16B |
| Shareholders' equity | $344.18M | $275.68M | $367.73M | $8.24B |
| Return on year-end equity | -23.4% | -14.1% | 0.4% | 4.6% |
| Shares outstanding | 49.40M | 41.24M | n/a | 195.90M |
Revenue, most recent five fiscal years
| Fiscal year | Staar Surgical Co | RxSight, Inc. | Warby Parker Inc. | Cooper Companies, Inc. |
|---|---|---|---|---|
| Latest | $239.44M Ended 2026-01-02 | $134.48M Ended 2025-12-31 | $871.90M Ended 2025-12-31 | $4.09B Ended 2025-10-31 |
| 1 year earlier | $313.90M Ended 2024-12-27 | $139.93M Ended 2024-12-31 | $771.32M Ended 2024-12-31 | $3.90B Ended 2024-10-31 |
| 2 years earlier | $322.42M Ended 2023-12-29 | $89.08M Ended 2023-12-31 | $669.76M Ended 2023-12-31 | $3.59B Ended 2023-10-31 |
| 3 years earlier | $239.44M Ended 2022-12-30 | $49.01M Ended 2022-12-31 | $598.11M Ended 2022-12-31 | $3.31B Ended 2022-10-31 |
| 4 years earlier | $230.47M Ended 2021-12-31 | $22.59M Ended 2021-12-31 | $540.80M Ended 2021-12-31 | $2.92B Ended 2021-10-31 |